[1] Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018,9:117. doi:10.1038/s41419-017-0063-y. [2] Sato C, Okuda K, Tamiya H, et al. Acute arterial thrombosis during postoperative adjuvant cisplatin-based chemotherapy for completely resected lung adenocarcinoma[J]. Intern Med, 2018,57:557-561. doi:10.2169/internalmedicine.8996-1. [3] Wang Q, Cheng N, Li X, et al. Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma[J]. Oncotarget, 2017,8:2558-2567. doi:10.18632/oncotarget.13708. [4] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54:95-117. doi:10.1146/annurev-pharmtox-011613-135959. [5] Rice AJ, Alvarez FJ, Davidson AL, et al. Effects of lipid environment on the conformational changes of an ABC importer[J]. Channels (Austin),2014,8:327-333. doi:10.4161/chan.29294. [6] Liu L, Zhang Q, Peng H. Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer[J]. J Chemother, 2023,35:39-52. doi:10.1080/1120009X.2022.2043515. [7] Li Z, Li S, Wen Y,et al. MiR-495 inhibits cisplatin resistance and angiogenesis in esophageal cancer by Targeting ATP7A[J]. Technol Cancer Res Treat, 2021,20:15330338211039127. doi:10.1177/15330338211039127. [8] Zhao X, Li X, Zhou L, et al. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3[J]. Cancer Sci, 2018,109:3068-3079. doi:10.1111/cas.13764. [9] Cao Y, Xie X, Li M, et al. CircHIPK2 Contributes to DDP resistance and malignant behaviors of DDP-resistant ovarian cancer cells both in vitro and in vivo through circHIPK2/miR-338-3p/CHTOP ceRNA pathway[J]. Onco Targets Ther, 2021, 14:3151-3165. doi:10.2147/OTT.S291823. [10] Adamska A, Falasca M. ATP-binding cassette transpor-ters in progression and clinical outcome of pancreatic cancer: What is the way forward[J]. World J Gastroenterol, 2018, 24:3222-3238. doi:10.3748/wjg.v24.i29.3222. [11] Huang C, Qin L, Chen S, et al. CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression[J]. Anticancer Drugs, 2023, 34:395-404. doi:10.1097/CAD.0000000000001465. [12] Wang X, Wang H, Jiang H, et al. Circular RNAcirc_0076305 promotes cisplatin (DDP) resistance of non-small cell lung cancer cells by regulating ABCC1 through miR-186-5p[J]. Cancer Biother Radiopharm, 2023, 38:293-304. doi:10.1089/cbr.2020.4153. [13] Zheng F, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis[J]. Biomed Pharmacother, 2020, 124:109828. doi:10.1016/j.biopha.2020.109828. [14] Zhou Y, Xu Z, Quan D, et al. Nuclear respiratory factor 1 promotes spheroid survival and mesenchymal transition in mammary epithelial cells[J]. Oncogene, 2018, 37:6152-6165. doi:10.1038/s41388-018-0349-2. [15] Liu X, Chen J, Zhang S, et al. LINC00839 promotes colorectal cancer progression by recruiting RUVBL1/Tip60 complexes to activate NRF1[J]. EMBO Rep, 2022, 23:e54128. doi:10.15252/embr.202154128. |